Yes R&P......this new clinical trial for PCNSL is a treatment for blood cancer. A big red letter day for the company, from no less, than probably at the moment - the worlds leading "brain" hospital Dana Farber.
PCNSL is rare however, with only 1500 new patients in the States each year.
What though of Central Nervous System (CNS) Lymphoma or microglioma......with see below gross sales of over one billion.
DF by virtue of this new clinical trial - suggesting Paxalisib may work in the CNS for blood cancers - how about then Paxalisib for microlioma.
This is not included in the studies of Priscilla Brastanous or anything else previously mentioned - but it would seem the door has opened up to a massive new opportunity for this drug.
Looking today for a briefing from the CEO on this weeks developments.
PDF (Single User License)USD 4500PDF (Corporate License)USD 5900
DESCRIPTION
Central Nervous System (CNS) Lymphoma or microglioma is a disease in which cancer cells are formed in the lymph tissue of the brain or spinal cord. This is observed primarily in patients with very weak immune systems, patients suffering from immunosuppression, and AIDS patients. Patients who have undergone recent kidney or other organ transplants are also at a high risk of having CNS lymphoma due to their low count of T-Cells or low level of immunity. The major symptoms of this disease include headaches, memory problem, drowsiness, seizures, nausea, vomiting, personality changes, throat infection, body weakness, and sometimes, even hearing loss and double vision. This disease may occur in all age groups; however, it is mostly noticed in people in the 50+ age group. The global central nervous system lymphoma market is estimated to surpass $1,127m by 2023, growing at an estimated CAGR of 6.65% from 2018 to 2023. The North America region is the largest market for CNS lymphoma.
KZA Price at posting:
92.0¢ Sentiment: Buy Disclosure: Held
